A combination of cyclophosphamide, methotrexate, vincristine and VP 16-213 (NSC 141 540) in the treatment of bronchogenic carcinoma
| Autor: | Ryssel Hj, Sonntag Rw, Kurt W. Brunner, Franco Cavalli, Eduard Hasler |
|---|---|
| Rok vydání: | 1977 |
| Předmět: |
Cancer Research
Vincristine medicine.medical_specialty Lung Neoplasms Cyclophosphamide Nausea Vomiting Gastroenterology 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Internal medicine medicine Carcinoma Humans Etoposide Podophyllotoxin business.industry Alopecia General Medicine Leukopenia medicine.disease Carcinoma Bronchogenic Methotrexate Oncology 030220 oncology & carcinogenesis Adenocarcinoma Drug Therapy Combination medicine.symptom business medicine.drug |
| Zdroj: | Tumori. 63(2) |
| ISSN: | 0300-8916 |
| Popis: | Thirty patients with bronchogenic carcinoma were treated with an 8–week induction therapy consisting of cyclophosphamide, methotrexate, vincristine and VP 16–213 (NSC 141 540). Those who achieved objective remission or tumor stabilization were then placed on an intermittent treatment schedule with the same drugs. Of the 30 patients, 17 had an objective response, 5 remained without change, and 8 progressed. Responses were more frequent among anaplastic (13/19) than epidermoid or adenocarcinoma (4/11). The toxicity consisted mainly of leucopenia, thrombopenia, alopecia, nausea and vomiting. The implications of these findings in the planning of further chemotherapeutic programs are discussed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|